

Contents

1 Introduction

W. Archie Bleyer, Karen H. Albritton,
Lynn A.G. Ries, and Ronald Barr

1.1	Introduction	1
1.2	Epidemiology	2
1.2.1	Classification System	2
1.2.2	Incidence	3
1.2.2.1	Age-Specific Incidence	3
1.2.2.2	Gender-Specific Incidence	3
1.2.2.3	Ethnicity-Specific Incidence	4
1.2.2.4	Types of Cancer	4
1.2.2.5	Trends in Incidence	6
1.2.3	Mortality and Survival	7
1.2.3.1	Age- and Gender-Specific Mortality	7
1.2.3.2	Ethnicity-Specific Mortality	8
1.2.3.3	Trends in Mortality	8
1.2.4	Survival	9
1.2.4.1	Conditional Survival	12
1.2.5	Etiology and Risk Factors	15
1.3	Diagnosis	15
1.3.1	Signs and Symptoms	15
1.3.2	Radiologic and Pathologic Considerations	16
1.4	Treatment	17
1.4.1	Choice of Treatment Setting and Specialist	17
1.4.2	Surgery	18
1.4.3	Radiation Therapy	18
1.4.4	Chemotherapy	18
1.4.5	Psychosocial and Supportive Care	19
1.4.6	Lack of Participation in Clinical Trials	20
1.4.7	Quality of Survival	21
1.5	Summary	22
	References	23

2 History of Adolescent Oncology

Cameron K. Tebbi

Epidemiology, Outcome, Access to Care and Role of Clinical Trials

2.1	Introduction	27
2.2	Background for Establishment of Adolescent/Young Adult Oncology as an Entity	29
2.3	Developments in the Psychosocial and Long-Term Care of Adolescent and Young Adult Oncology Patients	34
2.4	Summary	34
	References	34

3 Epidemiology and Etiology of Cancer in Adolescents and Young Adults

Jillian M. Birch and W. Archie Bleyer

3.1	Abstract	39
3.2	Introduction	40
3.3	Nosology and Cancer Spectrum	40
3.3.1	Diagnostic Classification	40
3.4	Incidence	41
3.4.1	Types of Cancers	42
3.4.2	Incidence Rates by Age and Diagnostic Group	45
3.4.3	Incidence by Gender	50
3.4.4	Temporal Trends in Incidence	50
3.5	Biological Differences	51
3.6	Etiology and Pathogenesis	52
3.6.1	Etiology	52
3.6.2	Genetic Predisposition and Genetic Susceptibility	54
3.7	Need for an Improved Classification System	55
3.8	Conclusions	55
	References	56

4 Access to Care Before and During Therapy

Karen H. Albritton and Tim Eden

4.1	Introduction	61
4.2	Access to Care Obstacles	62
4.2.1	Strategic/Financial Factors	63
4.2.2	Provider Issues	64
4.2.3	Personal Belief, Knowledge, Behavior	66
4.3	Delay in Diagnosis	66
4.4	Summary	67
	References	68

5 Older Adolescents and Young Adults with Cancer, and Clinical Trials: Lack of Participation and Progress in North America

W. Archie Bleyer, Troy Budd, and Michael Montello

5.1	Introduction	71
5.2	Deficit in Adolescent and Young Adult Participation in Clinical Trials	72
5.2.1	Race/Ethnicity	72
5.2.2	Gender	73
5.2.3	Residence	73
5.2.4	Individual Types of Cancer	73
5.3	Current Trends in Clinical Trial Participation by Older Adolescents and Young Adults with Cancer	73
5.4	Reasons for the Lack of Clinical Trial Participation by Older Adolescents and Young Adults with Cancer	73
5.5	Survival and Mortality Rates in Adolescents and Young Adults with Cancer	76
5.5.1	Survival Improvement: From Peak to Nadir	76
5.5.2	Survival by Gender and Ethnicity/Race	77
5.5.3	Survival by Individual Types of Cancer	77
5.5.4	Correlation of Survival Improvement and Mortality Reduction	77
5.6	Why the Lack of Progress in Older Adolescents and Young Adults with Cancer?	77
5.7	Summary	79
	References	80

6 Acute Lymphoblastic Leukemia

James Nachman, Giuseppe Masera, and W. Archie Bleyer

6.1	Introduction	83
6.2	Classification System and Methods	83
6.3	Incidence	84
6.3.1	Age-Specific Incidence	84
6.3.2	Gender-Specific Incidence	84
6.3.3	Racial/Ethnic Differences in Incidence	85
6.3.4	Incidence Trends	85
6.4	Risk Factors	85
6.5	Clinical Presentations and Molecular Biology	86
6.6	Treatment	88
6.7	Toxicity and Late Effects	91
6.8	Outcome	92
6.9	Summary and Conclusions	92
	References	96

7 Acute Myelogenous Leukemia

Ursula Creutzig and William G. Woods

7.1	Abstract	99
7.2	Introduction	99
7.3	Epidemiology/Etiology	100
7.3.1	Incidence	100
7.3.2	Etiology	100
7.3.3	Trends in survival	102
7.3.4	Prognostic factors	102
7.3.5	Treatment differences	103
7.4	Biology/Pathology	103
7.5	Diagnosis: Symptoms and Clinical Signs	104
7.6	Treatment/Management	104
7.7	Participation in Clinical Trials	105
7.8	Expected Outcome, Including Late Effects	106
7.9	Summary	107
	References	107

8 Hodgkin Lymphoma

Tanya M. Trippett, Alexis Mottl, Odile Oberlin, W. Archie Bleyer, and Louis S. Constine

8.1	Introduction	111
8.2	Epidemiology/Etiology	111
8.2.1	Incidence	111
8.2.1.1	Age-Specific Incidence	111
8.2.1.2	Gender-Specific Incidence	112
8.2.1.3	Racial/Ethnic Differences in Incidence	113
8.2.1.4	Trends in Incidence	113

8.3	Etiology/Risk Factors.	113
8.4	Pathology/Molecular Genetics	115
8.5	Symptoms and Clinical Signs	116
8.6	Diagnostic Testing	116
8.6.1	Hematology	116
8.6.2	Imaging	117
8.6.3	Surgery	117
8.6.4	Clinical Staging	117
8.7	Treatment/Management	118
8.7.1	General Treatment Consideration	118
8.7.2	Specific Treatment Trials	119
8.8	Outcome	122
8.8.1	Mortality.	122
8.8.2	Survival	122
8.8.3	Specific Treatment Trials.	122
8.9	Follow-up/Late Effects.	122
8.10	Conclusions.	123
	References	124

9 Non-Hodgkin Lymphoma

Catherine Patte, W. Archie Bleyer, and
Mitchell S. Cairo

9.1	Introduction	127
9.2	Epidemiology	128
9.2.1	Age-Specific Incidence.	128
9.2.2	Incidence of Histologic Types	129
9.2.3	Gender-Specific Incidence	129
9.2.4	Racial/Ethnic Differences in Incidence	129
9.3	Etiology/Risk Factors.	130
9.4	Histology/Cytogenetics.	130
9.5	Clinical Features.	132
9.6	Initial Work-Up and Staging	132
9.7	B-Cell non-Hodgkin Lymphoma (B-Non-Hodgkin Lymphoma)	134
9.7.1	Burkitt Lymphoma	134
9.7.2	Diffuse Large B-Cell Lymphoma.	135
9.7.3	Anaplastic Large Cell Lymphoma	136
9.7.3.1	Biology/Pathology.	136
9.7.3.2	Treatment/Management of S-ALCL.	137
9.8	Lymphoblastic Lymphoma.	140
9.8.1	Biology/Pathology	140
9.8.2	Treatment and Management.	141
9.9	Overall Survival	143
9.10	Conclusions.	144
	References	145

10 Central Nervous System Tumors in Adolescents and Young Adults

David A. Walker, Anne Bendel, Charles Stiller,
Paul Byrne, and Michael Soka

10.1	Introduction	152
10.2	Incidence, Pathology, and Etiology of CNS Tumors	153
10.2.1	Incidence of CNS Tumors in the Adolescent and Young Adult.	153
10.2.2	United States Population Databases: SEER and CBTRUS	153
10.2.3	Data from the United Kingdom	153
10.2.4	Histology Age-Incidence Patterns.	154
10.2.5	Etiology of CNS Tumors Adolescent and Young Adult.	156
10.2.5.1	Environmental and Exogenous Risk Factors	156
10.2.5.2	Predisposing Conditions.	159
10.2.5.3	Von Hippel-Lindau Syndrome	159
10.2.5.4	Tuberous Sclerosis.	161
10.2.5.5	Li-Fraumeni Syndrome	161
10.2.5.6	Multiple Endocrine Neoplasia	162
10.2.5.7	Cowden Disease	162
10.2.5.8	Turcot Syndrome	162
10.2.5.9	Gardner's Syndrome	162
10.2.5.10	Others Other Conditions with Increased Risk of CNS Tumors	162
10.2.5.11	Familial Aggregation of Brain Tumors.	163
10.3	Presentation, Assessment, Treatment, and Outcome	163
10.3.1	Clinical Presentation	163
10.3.2	Symptomatology	163
10.3.3	Multiprofessional Priorities for Adolescent- and Young Adult Centered Care	164
10.3.4	Assessment and Management.	165
10.3.4.1	Neurosurgery.	165
10.3.4.2	Radiotherapy Techniques	166
10.3.4.3	Chemotherapy	167
10.3.4.4	Integrated Care.	169
10.3.5	Intracranial GCTs – a Model Tumor of Adolescent and Young Adult Neurooncology Practice.	169
10.3.5.1	Epidemiology of CNS GCTs	169
10.3.5.2	Tumor Markers and Pathology	170
10.3.5.3	Literature Review	170

10.3.5.4	Phase 2 Studies in CNS GCTs	171
10.3.5.5	Retrospective Institutional and Multi-Institutional Reports	171
10.3.5.6	Registry Reports	172
10.3.5.7	Phase 3 Trials	172
10.3.5.8	Late Effects	175
10.3.5.9	Quality of Life Reports . . .	175
10.4	Survival Rates for CNS Tumors; SEER, and European Data	177
10.5	Conclusions.	178
	References	178

11 Soft-Tissue Sarcomas

Karen H. Albritton, Andrea Ferrari,
and Michela Casanova

11.1	Introduction	185
11.2	Epidemiology/Etiology	186
11.3	Biology/Pathology	187
11.4	Diagnosis/Symptoms and Clinical Signs . .	190
11.5	Treatment Management and Outcome. . .	190
11.5.1	Rhabdomyosarcoma	190
11.5.2	Adult-Type STS.	195
11.5.3	Synovial Sarcoma	197
11.6	Summary and Conclusions.	199
	References	199

12 Bone Sarcomas

Michael S. Isakoff, Michael J. Harris,
Mark C. Gebhardt, and Holcombe E. Grier

12.1	Introduction	203
12.2	Osteosarcoma	204
12.2.1	Epidemiology, Etiology, and Biology .	204
12.2.2	Pathology/Staging	205
12.2.3	Diagnosis	206
12.2.4	Treatment.	207
12.2.5	Late Effects	208
12.3	Ewing Sarcoma	209
12.3.1	Epidemiology and Etiology.	209
12.3.2	Biology and Pathology.	209
12.3.3	Diagnosis	211
12.3.4	Treatment.	212
12.3.5	Late Effects	214
12.4	Conclusions.	214
	References	215

13 Malignancies of the Ovary

Jubilee Brown, Thomas Olson, and Susan Sencer

13.1	Introduction	219
13.2	Epidemiology	220
13.3	Pathology and Biology	221
13.3.1	Germ-Cell Tumors.	221
13.3.2	Sex Cord-Stromal Tumors	223
13.3.3	Epithelial Tumors	223
13.3.4	Tumors of Low Malignant Potential. .	223
13.3.5	Presenting Signs and Symptoms . . .	223
13.3.6	Diagnostic Work-up.	224
13.3.7	Surgical Management	224
13.3.8	General Surgical Guidelines	224
13.3.9	Staging	226
13.3.10	GCTs: Surgical and Staging Considerations.	226
13.3.11	Teratomas: Surgical and Staging Considerations.	226
13.3.12	Dysgerminoma and Gonadoblastoma: Surgical and Staging Considerations. .	226
13.3.13	Sex Cord Stromal Tumors: Surgical and Staging Considerations. .	227
13.3.14	Epithelial Ovarian Cancer: Surgical and Staging Considerations. .	227
13.3.15	LMP Tumors: Surgical and Staging Considerations. .	227
13.4	Treatment.	229
13.4.1	GCTs: Treatment Issues.	228
13.4.2	Dysgerminomas: Treatment Issues . .	228
13.4.3	Sex Cord-Stromal Tumors: Treatment Issues	228
13.4.4	Granulosa Cell Tumors: Treatment Issues	229
13.4.5	Sertoli-Leydig Cell Tumors: Treatment Issues	229
13.4.6	Epithelial Tumors: Treatment Issues. .	230
13.4.7	Ovarian Tumors of LMP: Treatment Issues	230
13.5	Outcomes.	231
13.5.1	Germ-Cell Tumors.	231
13.5.2	Sex Cord-Stromal Tumors	231
13.5.3	Epithelial Tumors	231
13.5.4	Tumors of LMP.	232
13.6	Conclusions.	232
	References	234

14 Testicular Tumors

John W. Cullen and Robert Fallon

14.1	Introduction	237
14.2	Epidemiology and Etiology	237
14.3	Biology and Pathology	238
14.4	Clinical Symptoms and Evaluation	240
14.5	Staging and Risk Stratification	240
14.6	Treatment	241
14.7	Outcome	245
14.8	Late Effects	246
14.9	Conclusions	247
	References	247

15 Non-Germ-Cell Genitourinary Tract Tumors

Michael Leahy and W. Archie Bleyer

15.1	Introduction	249
15.2	Epidemiology and Etiology	250
15.3	Biology and Pathology	250
15.4	Clinical Presentations and Diagnosis	251
15.5	Treatment	251
15.6	Specific Tumors	252
	15.6.1 Kidney Tumors	252
	15.6.2 Urothelial and Bladder Tumors	253
	15.6.3 Prostate Cancer	255
15.7	Comparative Survival Rates	256
15.8	Conclusions	256
	References	256

16 Thyroid Cancer

Steven G. Waguespack and Samuel A. Wells

16.1	Introduction	259
16.2	Epidemiology	260
16.3	Differentiated Thyroid Carcinoma	260
	16.3.1 Epidemiology	260
	16.3.2 Etiology/Pathology	260
	16.3.3 Diagnosis and Clinical Presentation	262
	16.3.4 Management	263
	16.3.5 Late Effects	264
16.4	Medullary Thyroid Carcinoma	265
	16.4.1 Epidemiology	265
	16.4.2 Etiology/Pathology	265
	16.4.3 Diagnosis and Clinical Presentation	266
	16.4.4 Management	267
	16.4.5 Late Effects	268
16.5	Conclusions	268
	References	268

17 Malignant Melanoma

Cynthia E. Herzog, W. Archie Bleyer,
and Alberto S. Pappo

17.1	Introduction	272
17.2	Epidemiology	272
	17.2.1 Incidence Trends	272
	17.2.2 Race/Ethnic Differences in Incidence	274
	17.2.3 Gender Differences in Incidence	274
	17.2.4 Incidence by Anatomic Location	274
	17.2.5 Incidence Trends by Anatomic Location	275
	17.2.6 Stage and Thickness Trends in Incidence	275
17.3	Etiology and Risk Factors	276
	17.3.1 Xeroderma Pigmentosum	276
	17.3.2 Immunosuppression	276
	17.3.3 Familial Melanoma	277
	17.3.4 Nevus Phenotype and Environmental Factors	278
	17.3.5 The Sun and Other Ultraviolet Exposures	279
17.4	Clinical Presentation	279
17.5	Pathology	279
	17.5.1 Primary Skin Tumor	279
	17.5.2 Sentinel Node	281
	17.5.3 Lymph Node Dissection	281
17.6	Surgery	281
	17.6.1 Treatment of the Primary Tumor	282
	17.6.2 Lymph Node Mapping	282
	17.6.3 Lymph Node Dissection	283
	17.6.4 Surgical Treatment of Spitz Nevus	283
17.7	Staging	283
	17.7.1 Blood Tests	284
	17.7.2 Imaging Studies	284
	17.7.2.1 Ultrasound	284
	17.7.2.2 Computed Tomography	284
	17.7.2.3 Magnetic Resonance Imaging	284
	17.7.2.4 Positron Emission Tomography	285
17.8	Non-surgical Therapy	285
	17.8.1 Adjuvant therapy	285
	17.8.1.1 Interferon	285
	17.8.1.2 Radiotherapy	286
	17.8.2 Treatment of Measurable Disease	286
	17.8.2.1 Biotherapy	286
	17.8.2.2 Bio-chemotherapy	286
	17.8.2.3 Chemotherapy	286
	17.8.2.4 Vaccine Therapy	286
17.9	Prognosis	286
17.10	Conclusions	287
	References	287

18 Breast Cancer

Marianne Phillips, Banu Arun, and W. Archie Bleyer

18.1	Introduction	293
18.2	Epidemiology	294
	18.2.1 Incidence	294
	18.2.1.1 Ethnic Differences in Incidence	294
	18.2.1.2 Trends in Incidence	295
18.3	Diagnosis	295
18.4	Prognostic Characteristics	296
18.5	Treatment and Management	297
	18.5.1 Surgery	297
	18.5.2 Adjuvant Therapies	297
	18.5.3 Adjuvant Chemotherapy	298
	18.5.4 Adjuvant Endocrine Therapy	298
18.6	Outcome	299
	18.6.1 Survival	299
	18.6.2 Mortality	301
	18.6.3 Race/Ethnic Differences in Mortality	302
	18.6.4 Trends in Mortality	302
18.7	Special Considerations	302
	18.7.1 Fertility Issues	302
	18.7.2 Breast Cancer During Pregnancy	303
	18.7.3 Risk Reduction in Women with Inherited Predisposition to Breast Cancer	304
	18.7.4 Psychosocial Issues	305
18.8	Conclusions	306
	References	306

19 Liver Tumors

Marcio H. Malogolowkin, Arthur Zimmermann,
and Jack Plaschkes

19.1	Introduction	311
19.2	Epidemiology	312
	19.2.1 Incidence	312
19.3	Risk Factors and Etiology	313
19.4	Pathology and Biology	314
	19.4.1 HCC, Adult Type	314
	19.4.2 Fibrolamellar HCC	314
	19.4.3 Transitional Liver Cell Tumor	315
	19.4.4 Hepatoblastoma	315
19.5	Genetic and Molecular Mechanisms of Hepatocarcinogenesis	316
19.6	Clinical Presentation and Diagnosis	316
	19.6.1 Differential Diagnosis	317
	19.6.1.1 Embryonal (Undifferentiated) Sarcoma of the Liver	317

	19.6.1.2 Angiosarcoma and Cholangiocarcinoma	317
	19.6.1.3 Benign Tumors	317
	19.6.2 Tumor Staging	318
19.7	Treatment and Outcomes	319
	19.7.1 Adults with HCC	319
	19.7.2 Mortality and Survival	323
19.8	Liver Cancer in Adolescents and Young Adults	323
19.9	Future Perspectives	323
	References	325

20 Colorectal Cancer

Wayne L. Furman, D. Ashley Hill, and
Michael LaQuaglia

20.1	Introduction	331
20.2	Epidemiology	332
	20.2.1 Incidence	332
	20.2.2 Etiology	332
20.3	Biology/Pathology	333
20.4	Diagnosis: Symptoms and Clinical Signs	334
	20.4.1 Staging	335
20.5	Treatment/Management	335
	20.5.1 Surgery	336
	20.5.2 Radiation Therapy	337
	20.5.3 Adjuvant Chemotherapy	337
20.6	Outcome	337
20.7	Conclusions	338
	References	339

21 Models of Care and Specialized Units

Ian Lewis and Sue Morgan

21.1	Introduction	341
21.2	Aims of Care and the Patient Pathway	342
21.3	Teenagers and Young Adults Have Special Needs	342
	21.3.1 What do Young People Say They Need?	343
21.4	Developing a Pathway to Meet the Needs of Teenagers and Young Adults	344
	21.4.1 Centralization of Care and Access to Clinical Trials	344
	21.4.2 Improving Psychological, Social, and Educational Support	344

21.4.3	Cancer-Specific or Teenagers-and-Young-Adults-Specific Multidisciplinary Teams: is There a Conflict?	344
21.4.4	What Might a Single Pathway for Teenagers and Young Adults Look Like?	345
21.5	An Action Plan For Teenagers and Young Adults With Cancer	346
21.5.1	Past and Current Practice	346
21.5.2	Patterns of Care	346
21.5.2.1	Under 15 Years of Age	347
21.5.2.2	Aged 15 to 19 Years	347
21.5.2.3	Aged 20 Years and Over	349
21.5.3	Paradigms of Care, Communication, and Interaction	349
21.5.3.1	Children's Teams	349
21.5.3.2	Adult Teams	349
21.5.3.3	Teenage and Young Adult Teams	350
21.5.3.4	Teenage and Young Adult Units and Team	350
21.5.3.5	Virtual Units and Peripatetic Teams	351
21.6	Conclusions.	351
	References	352

22 Drug Compliance by Adolescent and Young Adult Cancer Patients: Challenges for the Physician

Benjamin Gesundheit, Mark L. Greenberg, Reuven Or, and Gideon Koren

22.1	Introduction	353
22.1.1	Compliance: Definition and History, Cultural Changes During the Last 50 Years.	354
22.2	Conclusions.	355
22.2.1	Cancer, Compliance, and Adolescence: Definitions and Interactions	355
22.2.1.1	Cancer and Adolescence.	355
22.3	Assessment of Compliance.	355
22.3.1	Indirect Methods	356
22.3.2	Direct Methods	356
22.3.3	Risk Factors and Predictors of Noncompliance	357
22.3.3.1	Features of Treatment and Adverse Effects of Medication	358
22.3.3.2	Demographic and Social Factors	358
22.3.3.3	Parents' and Child's Knowledge and Attitudes	358
22.4	Discussion	359
	References	361

23 Psychological Support for Adolescents and Young Adults

Christine Eiser and Aura Kuperberg

23.1	Introduction	365
23.2	From Diagnosis to Aftercare.	365
23.2.1	Diagnosis	366
23.3	Pediatric-, Adolescent- or Adult-Based Care?	367
23.3.1	When Treatment Ends	367
23.3.2	Follow-up Care.	367
23.4	Long-Term Issues	368
23.4.1	Body Image.	368
23.4.2	Fertility.	368
23.4.3	Employment	369
23.5	Adolescence to Young Adulthood – The Developmental Transition	369
23.5.1	Unique Challenges of Adolescence.	369
23.5.1.1	Positive Body Image	369
23.5.1.2	Sense of Identity and Independence	369
23.5.1.3	Sexual Identity	370
23.5.1.4	Future Career Goals	370
23.6	Treatment Approaches to Meet the Developmental Challenges of Adolescents and Young Adults	370
23.6.1	Impact Cancer, a Transition Model	371
23.7	Conclusions.	372
	References	372

24 Psychosocial Support

Brad J. Zebrack, Mark A. Chesler, and Anthony Penn

24.1	Introduction	375
24.2	Intellectual Issues.	376
24.2.1	Information About Cancer Diagnosis, Prognosis, and Treatment	376
24.2.2	Information Seeking	376
24.3	Practical Issues	376
24.3.1	The Hospitalization Experience, Including Pain and Painful Procedures	376
24.3.2	School and Work	377
24.4	Interpersonal Issues	377
24.4.1	Relationship with Parents	377
24.4.2	Relationships with Peers.	378
24.5	Emotional Issues	378
24.5.1	Psychological Distress	378
24.5.2	Posttraumatic Effects.	379
24.5.3	Coping	380
24.5.4	The Importance of Social, Peer, and Family Support.	380
24.5.5	Support Groups	380

24.6	Existential/Spiritual Issues	381
24.6.1	Uncertainty	381
24.7	Conclusion	382
References	382

25 Health-Related Quality of Life

Ernest R. Katz, Tasha Burwinkle, James W. Varni,
and Ronald D. Barr

25.1	Introduction	387
25.2	Dimensions Used in Measuring HRQL	388
25.3	Generic and Cancer-Specific Measures of HRQL	389
25.4	Measuring HRQL in Adolescents vs Adults .	389
25.5	Self Report vs. Proxy Reports (i.e., Parent, Provider, or Caregiver)	390
25.6	HRQL Measurement and Clinical Cancer Care	390
25.7	Selected HRQL Measures for Adolescents and Young Adults	392
25.8	Barriers to the Use of HRQL Measures and Proposed Solutions	394
25.9	Facilitating Clinical Decision-Making with HRQL Data	394
25.10	Risk Prediction	395
25.11	Conclusions	396
References	396

26 Rehabilitation and Exercise

Marilyn J. Wright

26.1	Introduction	401
26.2	General Principles of Rehabilitation	402
26.3	Rehabilitation and Exercise Needs	402
26.3.1	Body Structure and Function	403
26.3.2	Activity and Participation	404
26.4	Intervention	404
26.4.1	Physical Activity	404
26.4.1.1	Precautions and Contraindication	406
26.4.2	Other Specific Interventions	406
26.4.3	Facilitating Participation	408
26.4.4	Intervention for the Acutely Ill, Isolated, or Hospitalized Patient	408
26.4.5	Palliative Care	408
26.5	Conclusion	409
References	409

27 Adolescent and Young Adult Cancer Survivors: Late Effects of Treatment

Smita Bhatia, Wendy Landier, Andrew A. Toogood,
and Michael Hawkins

27.1	Introduction	411
27.2	Medical Issues	413
27.2.1	Late Mortality	413
27.2.2	Second Primary Neoplasms	413
27.2.2.1	Second Primary Neoplasms after Hodgkin Lymphoma	414
27.2.2.2	Second Primary Neoplasms after Non-Hodgkin Lymphoma	415
27.2.2.3	Second Primary Neoplasms after Testicular Cancer	415
27.2.2.4	Second Primary Neoplasms after Breast Cancer	415
27.2.3	Cardiovascular Function	415
27.2.4	Pulmonary Function	417
27.2.5	Endocrine Function	418
27.2.6	Pituitary Function	419
27.2.7	Gonadal Function	419
27.2.8	Other Endocrinopathies	420
27.2.9	Genitourinary Function	420
27.2.9.1	Renal	420
27.2.9.2	Bladder	421
27.2.10	Gastrointestinal Function	421
27.2.11	Musculoskeletal and Related Tissues . .	422
27.3	Delivering Survivorship Care	423
27.4	Recommendations for Screening	423
27.5	Cancer Survivorship – Future Research Opportunities	424
References	426

28 Ethical Issues for the Adolescent and Young Adult Cancer Patient: Assent and End-of-Life Care

Susan Shurin and Eric Kodish

28.1	Introduction	431
28.2	Mark's Story at Diagnosis	432
28.2.1	July 20, 1998	432
28.2.1.1	Case Report Presented by the Attending Physician	432
28.2.1.2	Mark's Mother Sue's Diary Entry, July 20, 1998	432
28.2.1.3	Mark's Father George's Conversation at the Chatter- box Café, July 20, 1998	433
28.2.1.4	Mark's Email to his Girlfriend, July 20, 1998	433

28.3	Mark's Story After Several Relapses	433
28.3.1	January 7, 2000	433
28.3.1.1	Case Report Presented by the Attending Physician at Tumor Board.	433
28.3.1.2	Sue's Diary Entry, December 31, 1999	433
28.3.1.3	George's Conversation with his Buddies at the Chatter- box Café, January 7, 2000	434
28.3.1.4	Mark's Email to his Girlfriend, January 1, 2000.	434
28.4	Reflections on the Concept of Assent	434
28.4.1	Assent for Treatment and Assent for Research	435
28.4.2	Assent at Diagnosis and Assent at Relapse	435
28.4.3	Assent as Empowerment or Assent Negotiated?	436
28.5	Reflections on the Concept of Palliative Care	436
28.5.1	Professional and Family Roles	436
28.5.2	Involvement of Adolescents in Decisions About Their Own Care	437
28.5.3	Impact of Symptom Control on Therapeutic Decisions	437
28.5.4	Palliative Care Issues at Diagnosis	437
28.5.5	Palliative Care Issues at the End of Life	438
28.6	Biological Basis for Ongoing Development of Competence in Adolescents and Young Adults	438
28.6.1	An Alternate Scenario	439
References		439

29 Access to Care after Therapy

Karen E. Kinahan, David R. Freyer, Beverly Ryan,
and Mary Baron Nelson

29.1	Introduction	443
29.2	Survivors of Young Adult Cancer	443
29.3	Young Adult Survivors of Childhood Cancer	444
29.3.1	Transition of Care: Background and Principles	444
29.3.2	Transition of Care: Key Issues for Childhood Cancer Survivors	445
29.3.3	Transitional Care Concerns Among Nurses in the Children's Oncology Group.	446

29.3.4	Models of Transitional Care As Reported By Nurses in the COG.	447
29.3.4.1	Model 1: Adult Practitioner Model.	448
29.3.4.2	Model 2: Resource Model	448
29.3.4.3	Model 3: Switch Model	448
29.3.4.4	Model 4: Comfort Model.	449
29.4	Conclusions.	449
References		449

30 Future Health of Survivors of Adolescent and Young Adult Cancer

Melissa M. Hudson and Kevin C. Oeffinger

30.1	Introduction	451
30.2	Healthcare of Cancer Survivors	452
30.2.1	Risk-Based Healthcare of Survivors	454
30.2.2	Asymptomatic Survivors	454
30.2.3	Symptomatic Survivors	455
30.3	Promoting Healthy Lifestyles	456
30.3.1	Health Behavior Counseling of the Adolescent/Young Adult Cancer Survivor	456
30.3.2	Lifestyle Recommendations for the Adolescent/Young Adult Cancer Survivors.	457
30.3.3	Diet and Physical Activity	457
30.3.4	Tobacco Use	459
30.3.5	Alcohol.	460
30.3.6	Sun Protection	462
30.3.7	Dental Care	462
30.4	Summary	462
References		463

31 Information and Resources for Young Adults and Adolescents with Cancer

David R. Freyer and Leonard J. Mattano

31.1	Introduction	469
31.2	The Value of Sharing Medical Information	469
31.3	Methods of Sharing Medically Related Information.	470
31.4	The Expanding Role of Internet-Based Health and Medical Information Resources.	470
31.5	Using This Chapter	471
References		486

32 Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Healthcare Team

David R. Freyer and Ronald D. Barr

32.1	Introduction	493
32.2	Younger Adolescents: the Financially 'Dependent Patient'	494
	32.2.1 Case Example	494
	32.2.2 Major Financial Issues	494
32.3	Older Adolescents and Young Adults: the Financially Independent Patient or Survivor	495
	32.3.1 Case Example: The Young Adult On Therapy	496
	32.3.2 Major Financial Issues	496
	32.3.2.1 Health Insurance.	496
	32.3.2.2 Reduced Work and Loss of Income	496
	32.3.3 Case Example: The Adolescent and Young Adult Survivor of Childhood Cancer	497
	32.3.4 Major Financial Issues	497
	32.3.4.1 Employment	497
	32.3.4.2 Health and Life Insurance	500
	32.3.4.3 Other Factors Threatening Financial Stability: Education and Marital Status	502
32.4	Conclusions.	502
	References	503

33 Challenges and Opportunities – The Way Ahead

W. Archie Bleyer, Karen Albritton, Stuart Siegel,
Marianne Phillips, and Ronald Barr

33.1	Introduction	505
33.2	Current Status	506
33.3	Reasons for Lack of Progress	507
	33.3.1 Personal/Patient.	508
	33.3.2 Family/Community	509
	33.3.3 Health Professional	509
	33.3.4 Societal/Cultural.	511
33.4	Prioritization of Challenges and Potential Solutions	511
	33.4.1 Personal/Patient.	511
	33.4.2 Family/Community	511
	33.4.3 Health Professional	512
	33.4.4 Societal/Cultural.	512
33.5	Longer Time to Diagnosis in Adolescents and Young Adults than in Children	512
33.6	Place of Diagnosis and Treatment: Pediatric versus Adult Care Specialists and Facilities	513
33.7	Implications for Other Age Groups	515
33.8	International Perspectives and Global Challenge	515
33.9	Future Directions and Interim Solutions	516
33.10	Conclusions.	517
	References	518



<http://www.springer.com/978-3-540-40842-0>

Cancer in Adolescents and Young Adults

Bleyer, A.W.; Barr, R.D. (Eds.)

2007, XXIII, 534 p., Hardcover

ISBN: 978-3-540-40842-0